18 results about "Distant metastasis" patented technology

Presented herein are systems and methods that provide automated analysis of 3D images to classify representations of lesions identified therein. In particular, in certain embodiments, approaches described herein allow hotspots representing lesions to be classified based on their spatial relationship with (e.g., whether they are in proximity to, overlap with, or are located within) one or more pelvic lymph node regions in detailed fashion.

The application discloses a nasopharyngeal carcinoma prognosis feature determination method, system and device and a storage medium. The method comprises the following steps: pathological image preprocessing, color normalization based on dye separation is used to standardize the dyeing of the pathological image; a segmentation network is used to automatically segment the lesion area of the preprocessed pathological image to obtain a segmented image; the segmented image is cropped to obtain a target image block; principal component analysis is used to reduce the dimension of the target image block to obtain reduced dimension data; a clustering algorithm is used to perform unsupervised autonomous learning on the reduced dimension data to obtain pathological image features; and finally, the pathological image features are screened through feature inspection to determine a prognosis pathological feature set. The application can obtain and screen key image features of pathological images closely related to local area recurrence and distant metastasis of nasopharyngeal carcinoma from pathological images to assist in prognosis prediction of nasopharyngeal carcinoma, and can be widely applied to the technical field of image processing.

The invention discloses an in-situ'tumor capture 'type electrostatic spinning patch as well as a preparation method and application thereof. The invention relates to an in-situ'tumor capture 'type electrostatic spinning patch for sequential treatment in and after pancreatic cancer resection. The electrostatic spinning patch comprises a gelatin / hyaluronic acid-based hemostatic sponge layer with a capture function, a gemcitabine slow-release layer and a polycaprolactone backing layer. According to the invention, the dual core requirements of hemostasis and cancer resistance during operation and after operation are integrated, and a long-acting protective barrier is constructed at the local part of the operation through continuous drug delivery. Therefore, the efficiency of removing residual lesions is remarkably improved, local recurrence and distant metastasis of tumors can be effectively prevented, and finally a safer, more lasting and more comprehensive comprehensive treatment new strategy is provided for pancreatic cancer postoperative patients.

The invention belongs to the field of polymer chemistry and biomedical engineering, and discloses a construction method and application of a biomimetic membrane coated drug-loaded nano system. According to the system disclosed by the invention, small-molecule traditional Chinese medicine (sinomenine) is loaded in mesopores, and homologous cell membranes wrap drug-loaded nanoparticles to obtain a final nano-drug system which can effectively and passively target nasopharyngeal carcinoma cells. The sinomenine can cooperate with photothermal therapy to jointly induce mitochondrial injury, promote cell apoptosis and cause ICD immunoreaction, the sinomenine inhibits PD-L1 expression to relieve immunosuppression of T cells, meanwhile, infiltration of cytotoxic T cells in tumor sites is increased, distant metastasis of nasopharyngeal carcinoma can be inhibited by inhibiting MMPs and PD-L1, and the nasopharyngeal carcinoma can be inhibited by inhibiting MMPs and PD-L1. Therefore, the effects of enhancing nasopharynx cancer immunotherapy and inhibiting metastasis are achieved.

The invention relates to the technical field of biological medicine, and particularly discloses application of an ICAM1 inhibitor in preparation of a nasopharynx cancer resistant circulating tumor cell cluster preparation. According to the application, expression of a shRNA silent gene ICAM1 is utilized, in-vitro experiments prove that proliferation, migration and invasion ability of nasopharyngeal carcinoma cells can be remarkably reduced by inhibiting the ICAM1, formation of circulating tumor cell clusters and angiogenesis are inhibited, after the nasopharyngeal carcinoma cells are treated by cis-platinum drugs, the activity of ICAM1 silent group cells is remarkably reduced, and the activity of the ICAM1 silent group cells is remarkably reduced. Experimental results show that a relatively low ICAM1 expression level is related to relatively high chemotherapeutic drug sensitivity. The ICAM1 inhibitor shICAM1 provided by the invention has important application value in preparation of a preparation for specifically targeting nasopharyngeal carcinoma circulating tumor cell clusters, and a brand new treatment scheme is provided for solving the problem of nasopharyngeal carcinoma distant metastasis.

The utility model relates to the technical field of tumor cell metastasis models, in particular to a breast cancer circulating tumor cell remote metastasis model which comprises a base and a fixing rod, the fixing rod is fixedly connected to the base, the fixing rod is fixedly connected with a brain metastasis model, a placing component is installed on the brain metastasis model, and the placing component is fixedly connected with the brain metastasis model. The placing part comprises an inclined plate, a fixed plate, a movable plate, a pressed plate, a straight spring and a collecting box, the inclined plate is fixedly connected in the brain metastasis model, the clamping plate clamps small balls with different colors through the matching effect of the extrusion rod, the movable plate, the collecting box and other parts, the small balls can be taken out by pulling the clamping plate, and the small balls can be conveniently taken out. And residual water is left in the collecting box, so that the small balls can be quickly taken out, meanwhile, no water drips on the outer surface of the model, the situation that the transparency of the model is affected by water marks generated on the outer surface of the model due to water dripping is avoided, and the transparency of the organ model and the cleanliness of a placement environment are guaranteed.

A technology is described which provides a platform for improving the penetration into tumors in a subject of cancer treatment and cancer imaging agents for greater patient benefit. The invention in particular overcomes two challenges for use of tumor targeting methods for solid tumors: poor penetration and the immunosuppressive nature of the tumor microenvironment. The platform described here allows long-term, in vivo production of iRGD. In a preferred embodiment, CAR-T cells are engineered to secrete iRGD, a tumor-penetrating peptide to achieve tissue-penetrating delivery of drugs and imaging agents in a tumor-specific manner. The peptide acutely permeabilizes the tumor vasculature by binding to αv integrins and neuropilin, but in a tumor-specific manner. This method produces a modification in the tumor microenvironment that enhances drug access into the tumor, prevents distant metastasis of the tumor cells, and allows long-term iRGD therapy without the need for repeated injections of iRGD.

The invention relates to the technical field of biological medicines, and discloses a FAP-targeted polymeric compound as well as a preparation method and application thereof. The chemical structure of the FAP-targeting polymeric compound is shown as any one of formulas (1)-(3), and the FAP-targeting polymeric compound comprises 3-6 targeting parts of fibroblast activating protein alpha (FAP-alpha). Compared with the existing compound, the FAP-targeted polymeric compound provided by the invention has higher tumor uptake and longer tumor residence time; in the diagnosis and treatment of FAP positive tumors, the FAP-targeted polymeric compound can clearly display the position and range of the tumors, discover the distant metastasis of the tumors in time, and provide more comprehensive disease assessment.

The invention belongs to the field of new application of medicines, and particularly relates to application of Sivelestat in preparation of cancer radiotherapy adjuvant medicines. According to the invention, Sivelestat which has been used for acute respiratory distress syndrome is creatively applied to tumor radiotherapy, and the Sivelestat inhibits the activity of neutrophil elastase and effectively blocks the formation of a neutrophil outer trapping net induced by radiotherapy, so that the invasion of tumor cells and the abnormal generation of blood vessels are inhibited, and an immunosuppression microenvironment is established. The application not only maintains the local killing effect of radiotherapy on primary tumors, but also cuts off the key path from radiotherapy to NETs to metastasis from the mechanism, and significantly reduces the risk of tumor recurrence and distant metastasis after radiotherapy. The traditional Chinese medicine composition has the transformation advantage of new use of old medicines, is clear in clinical safety, and is suitable for adjuvant therapy of various solid tumors.

The invention belongs to the field of kits, and particularly relates to application of a reagent for detecting HMGXB3 gene and protein expression level thereof in preparation of a kit for screening breast cancer metastasis or evaluating breast cancer prognosis. On the basis of early clinical discovery, in-vivo and in-vitro experiments and clinical data statistical analysis further verify that high expression of HMGXB3 can promote the distant metastasis behavior of the breast cancer, and the distant metastasis of the breast cancer can be inhibited after the HMGXB3 is knocked down; the invention also verifies that high expression of HMGXB3 can lead to obvious shortening of the total lifetime and the distant metastasis lifetime of the breast cancer patient, which provides an effective basis for the patient to take related treatment measures or decisions, and has a good clinical application prospect.

The invention discloses a composition, which comprises engineering bacteria for expressing TLS induced protein and mesenchymal stem cells, and can effectively induce TLS formation, inhibit tumor growth, improve systemic immunity, inhibit distant metastasis and prevent tumor recurrence in tumor tissues, thereby providing a new technical path for enhancing the universality and accessibility of immunotherapy. And an innovative platform is provided for the research on a combined treatment scheme of tumor immunotherapy.

The invention belongs to the field of new application of drugs, and particularly relates to application of AZD5069 in preparation of cancer radiotherapy adjuvant drugs. The invention discloses a novel application of a CXCR2 receptor antagonist AZD5069 in preparation of an adjuvant drug for tumor radiotherapy. The invention aims to solve the core clinical problem that the tumor remote metastasis risk may be increased although the tumor can be locally killed by radiotherapy. Through combined application of AZD5069 and radiotherapy, collection and activation of neutrophile granulocytes activated by radiotherapy to a metastasis site can be inhibited by utilizing the capability of the AZD5069 for specifically blocking a CXCLs / CXCR2 signal channel, so that tumor metastasis is effectively prevented while the local curative effect of radiotherapy is maintained, and dual treatment targets of local control and whole body metastasis resistance are realized.

This invention discloses a joint detection system for nasopharyngeal carcinoma lesion segmentation and metastasis based on HSL-Net, including a weight management module for checking whether weight coefficients have been preset in the system; if the system has not preset weight coefficients, the model training module is activated; if the system has preset weight coefficients, the joint detection module is activated; the model training module generates weight coefficients for HSL-Net used for lesion segmentation and pathological staging classification; the joint detection module loads the weight coefficients onto the HSL-Net to perform lesion segmentation and pathological staging classification on the input image, and outputs the results after accuracy judgment, thus completing the joint detection; this invention introduces a novel neural network architecture based on a large-kernel convolutional global guided state space mechanism to achieve accurate segmentation of the spatial structure of the primary nasopharyngeal carcinoma lesion and sensitive identification of distant metastasis risk, thereby enhancing the comprehensive ability of intelligent disease diagnosis.

The present application relates to the technical field of antitumor drugs, and provides a drug delivery system loaded with artificial metalloenzyme and polyphenol compound as well as a preparation method and application thereof.The present application takes metal clusters fixed in a protein cavity as artificial metalloenzyme, takes abundant edible polyphenol compound as a biological active substrate of the artificial metalloenzyme, and simultaneously adopts pH-sensitive liposomes to encapsulate the artificial metalloenzyme and the polyphenol compound.The pH-sensitive liposomes are stable at physiological pH, but are broken in an acidic tumor microenvironment to release the artificial metalloenzyme and the polyphenol compound; the artificial metalloenzyme accelerates oxidation and polymerization of the polyphenol compound in an environment around tumor tissues and in tumor cells to form a hydrogel self-assembly, and the self-assembly can effectively inhibit growth and distant metastasis of an in-situ tumor.

The invention discloses an HSL-Net-based nasopharyngeal carcinoma lesion segmentation and metastasis joint detection system, which comprises a weight management module used for retrieving whether a weight coefficient is preset in the system or not; if it is judged that the system does not have the preset weight coefficient, activating a model training module; if it is judged that the system has preset the weight coefficient, activating a joint detection module; the model training module is used for generating weight coefficients of HSL-Net for focus segmentation and pathological stage classification; the joint detection module is used for carrying out focus segmentation and pathological staging classification on an input image by the HSL-Net loaded with a weight coefficient, carrying out accuracy judgment on a result and then outputting the result to finish joint detection; according to the invention, by introducing a novel neural network architecture based on a large-kernel convolution overall guidance state space mechanism, accurate segmentation of a nasopharyngeal carcinoma primary focus space structure and sensitive identification of a distant metastasis risk are realized, so that the comprehensive ability of disease intelligent diagnosis is enhanced.

The application provides a TRIM29 inhibitor and its application in the preparation of a drug for resisting pancreatic ductal adenocarcinoma, and belongs to the technical field of biological medicine. The application provides the application of the TRIM29 inhibitor in the preparation of a drug for resisting pancreatic ductal adenocarcinoma, and the amino acid sequence of the TRIM29 is shown as SEQ ID NO. 3. It is proved by in-vivo and in-vitro functional experiments that the inhibition of the TRIM29 activity can significantly block the EMT process, migration and invasion ability of PDAC cells, inhibit the microvessel invasion and distant metastasis in the body, and has no obvious toxicity to normal cells, and has good biological safety and drugability. The application further provides a TRIM29 inhibitor, which can be used alone to block the early metastasis of PDAC, and can also be combined with a first-line clinical chemotherapy drug and an immunotherapy drug to synergistically enhance the anti-tumor effect, significantly improve the treatment benefit of the existing clinical scheme, and has a very high clinical transformation value.

The invention discloses an application of scurriboside B or a derivative thereof in preparation of a medicine for treating gastric cancer. The structure of the scurriboside B is shown in the specification. The Sanbao lignin B or the derivative of the Sanbao lignin B down-regulates expression of invasion and metastasis related protein, inhibits migration and invasion of gastric cancer cells, reduces the risk of tumor distant metastasis and blocks malignant progression of gastric cancer by regulating an EMT related signal channel. Aiming at the pain points of low proportion of HER2 positive patients, easy generation of drug resistance of targeted drugs, limited immune treatment benefit crowds and the like in current gastric cancer treatment, the Sancurbatin B as a brand new natural anti-tumor active component provides a new candidate target and direction for research and development of anti-gastric cancer drugs. The compound not only can be independently developed into an anti-gastric cancer drug, but also can be used in combination with chemotherapy, targeted therapy or immunotherapy drugs to synergistically improve the treatment effect, and has extremely high clinical transformation value and market application potential.